No Data
No Data
Reported Earlier, Praxis Announces 2025 Milestones: Advancing Relutrigine, Ulixacaltamide, And Rare Disease Programs With $470M In Cash Reserves
Praxis Precision Medicines Highlights Late-Stage Clinical Trial Advancements and 2025 Milestones
Press Release: Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Express News | Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
Express News | Praxis Precision Medicines : Sales Agreement Prospectus Covering Offering up to $250 Mln of Common Stock That May Be Issued From Time to Time
BarfBag : Check out $Pagaya Technologies (PGY.US)$ solid AH